title: Bortezomib and bilateral herpes zoster.
abstract: Bortezomib is a proteasome inhibitor that has proven to be a very effective treatment for multiple myeloma. There is considerable debate about the potential for reactivation of the varicella zoster virus (VZV) in patients with multiple myeloma during treatment with bortezomib. This report describes the case of a 70-year-old patient with multiple myeloma that developed bilateral herpes zoster shortly after being treated with bortezomib. Furthermore, it emphasizes the importance of using an antiviral prophylaxis with acyclovir in these patients treated with bortezomib.
authors.affiliation: University of Trieste, Department of Dermatology and Venereology, Trieste, Italy. nickdimeo@libero.it
authors.forename: Nicola
authors.initials: N
authors.lastname: di Meo
authors.forename: Serena
authors.initials: S
authors.lastname: Bergamo
authors.forename: Adina
authors.initials: A
authors.lastname: Dondas
authors.forename: Giusto
authors.initials: G
authors.lastname: Trevisan
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D017809:Fatal Outcome; D006562:Herpes Zoster / Q000139:chemically induced* / Q000517:prevention & control / Q000821:virology; D014645:Herpesvirus 3, Human / Q000502:physiology; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000821:virology; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib